- A 60-year-old male with poorly controlled type 2 diabetes treated with canagliflozin presents with fever, perineal pain, and swelling. Examination reveals erythema and tenderness extending to the scrotum. This presentation is highly concerning for which rare but life-threatening adverse effect associated with his medication class?
Answer: Fournier's gangrene
Fournier's gangrene is a rare but severe necrotizing fasciitis of the perineum that has been associated with the use of SGLT2 inhibitors. The presentation of fever, severe pain, and rapidly progressing soft tissue inflammation in the genital area is classic for this condition, which is a surgical emergency. While genital mycotic infections (A) are common, they are not typically associated with systemic signs like fever or the rapid progression of necrosis. Urosepsis (B) is possible, but the physical exam findings are pathognomonic for Fournier's gangrene. The presentation is inconsistent with anaphylaxis (D).
- An elderly patient is initiated on ertugliflozin. Baseline labs include a serum creatinine of 1.1 mg/dL and hematocrit of 42%. After one month, which of the following laboratory changes would be an expected pharmacodynamic effect of the drug and not necessarily alarming?
Answer: Serum creatinine increases to 1.3 mg/dL and hematocrit increases to 45%.
SGLT2 inhibitors cause a predictable hemodynamic effect characterized by an initial, mild, and reversible drop in the glomerular filtration rate (GFR). This manifests as a small increase in serum creatinine. Additionally, the osmotic diuresis caused by the drug leads to hemoconcentration, which is reflected by a modest increase in hematocrit. Therefore, a slight rise in both creatinine and hematocrit is an expected finding. A decrease in creatinine (B) is the opposite of the expected effect. Significant hyperkalemia or metabolic acidosis (C) would be alarming. Hyponatremia (D) is not a typical effect; mild hypernatremia from dehydration is more likely.
- A 58-year-old male with type 2 diabetes and a BMI of 34 kg/m² is initiated on subcutaneous semaglutide. Two weeks later, he reports persistent nausea and a feeling of being "full after only a few bites." Which of the following best explains the patient's symptoms and represents an appropriate initial counseling point?
Answer: The symptoms are due to delayed gastric emptying; counseling to eat smaller, more frequent meals is appropriate.
GLP-1 agonists, including semaglutide, slow gastric emptying, which contributes to satiety but also commonly causes gastrointestinal side effects like nausea and early fullness. The most appropriate initial management is dietary modification, such as eating smaller, more frequent meals. While CNS effects on satiety exist (B), the prominent postprandial fullness points directly to delayed gastric emptying. While pancreatitis is a risk (C), these symptoms are the most common expected side effects and do not alone warrant immediate discontinuation. The symptoms are not due to excessive insulin secretion (D), and taking the drug with a large meal would likely worsen the symptoms of fullness.
- A clinician is considering initiating either liraglutide or dapagliflozin for a patient with type 2 diabetes and established cardiovascular disease. A detailed family history reveals that the patient's mother was diagnosed with medullary thyroid carcinoma. This finding represents a specific contraindication related to which of these medications?
Answer: Liraglutide, due to the black box warning for risk of thyroid C-cell tumors.
GLP-1 agonists, including liraglutide, carry a black box warning for the risk of thyroid C-cell tumors (including medullary thyroid carcinoma, MTC) based on rodent studies. This warning contraindicates their use in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). SGLT2 inhibitors like dapagliflozin do not carry this warning. Therefore, the family history is a specific contraindication for liraglutide.
- A 45-year-old woman is initiated on dapagliflozin for type 2 diabetes. One month later, she calls the clinic complaining of perineal itching and discharge. Which of the following is the most appropriate next step in management?
Answer: Prescribe a short course of a topical or oral antifungal agent and counsel on hygiene measures.
Genital mycotic infections (e.g., vulvovaginal candidiasis) are a very common side effect of SGLT2 inhibitors due to increased glucose in the urine (glycosuria), which promotes fungal growth. The standard of care is to treat the infection with an appropriate antifungal medication while continuing the SGLT2 inhibitor, and to educate the patient on proper hygiene. It is not an allergic reaction (A). While the side effect may recur, immediate discontinuation or switching (C) is not necessary as it is often manageable. The symptoms are classic for a yeast infection, not a UTI, so a urine culture is not the primary next step (D).
- A patient with type 2 diabetes and atherosclerotic cardiovascular disease is treated with both liraglutide and empagliflozin. Combining these two classes is rational because their mechanisms are complementary. Which statement accurately describes a key risk that is not significantly increased by this combination compared to either agent as monotherapy?
Answer: Risk of severe hypoglycemia
The risk of severe hypoglycemia with either GLP-1 agonists or SGLT2 inhibitors as monotherapy (or in combination with drugs like metformin) is very low. This is because the GLP-1 agonist mechanism is glucose-dependent and the SGLT2 inhibitor mechanism is insulin-independent. Combining them does not substantially increase hypoglycemia risk. In contrast, the risk of dehydration (A) can be additive, as GLP-1s can cause GI fluid loss and SGLT2s cause osmotic diuresis. Dehydration from the GLP-1 agonist could potentially increase the risk of SGLT2i-induced DKA (C). The financial cost (D) is certainly increased.
- A patient with type 2 diabetes taking metformin and glimepiride is started on dulaglutide. The physician counsels the patient on an increased risk of hypoglycemia. This increased risk is primarily an interaction between dulaglutide and which existing medication?
Answer: Glimepiride, because its insulin secretion is glucose-independent, which circumvents the safety mechanism of the GLP-1 agonist.
GLP-1 agonists like dulaglutide stimulate insulin secretion in a glucose-dependent manner, meaning they have a low intrinsic risk of hypoglycemia. However, sulfonylureas like glimepiride stimulate insulin release from pancreatic beta-cells regardless of the blood glucose level. When these agents are combined, the GLP-1 agonist's potentiation of insulin release can lead to hypoglycemia because the sulfonylurea's action is not regulated by glycemia. Metformin has a very low risk of causing hypoglycemia. There are no significant pharmacokinetic interactions as described in (D).
- A 42-year-old patient with type 2 diabetes and a BMI of 38 kg/m² has an HbA1c of 8.2% on metformin monotherapy. The primary goal for adding a second agent is significant weight reduction in addition to glycemic control. Which of the following represents the best therapeutic strategy?
Answer: Initiate a GLP-1 agonist, as this class generally produces more robust weight loss than SGLT2 inhibitors.
While both GLP-1 agonists and SGLT2 inhibitors are associated with weight loss, clinical evidence consistently shows that GLP-1 agonists (especially agents like semaglutide and tirzepatide) lead to significantly greater average weight loss. This is due to their combined effects of delayed gastric emptying and central nervous system-mediated appetite suppression. SGLT2 inhibitors cause weight loss through glycosuria (losing ~200-300 kcal/day), but this effect is typically less pronounced than with GLP-1 agonists. Therefore, for a patient where weight loss is a primary goal, a GLP-1 agonist is the superior choice.
- A physician is reviewing a patient's chart to determine if they are a candidate for dapagliflozin therapy for its heart failure benefits. The patient does not have diabetes. Which of the following findings would be an absolute contraindication to initiating therapy?
Answer: The patient is currently maintained on hemodialysis.
SGLT2 inhibitors, including dapagliflozin, are contraindicated in patients with end-stage renal disease or those on dialysis. Their efficacy is dependent on glomerular filtration, and their safety has not been established in this population. They can be initiated in patients with an eGFR as low as 25-30 mL/min/1.73m² for indications like heart failure or CKD (A). A history of a UTI is a precaution, not a contraindication (B). An HbA1c of 5.5% is normal, and these drugs are approved for use in patients without diabetes for heart failure and CKD (D).
- A patient with type 2 diabetes tells his physician, "My new medication must be working well. I've noticed I'm urinating more frequently, and my urine sometimes has a sweet smell." This patient's experience is most characteristic of the mechanism of which of the following medications?
Answer: Empagliflozin
The patient's symptoms of increased urination (polyuria) and sweet-smelling urine are classic signs of glycosuria (glucose in the urine). SGLT2 inhibitors, such as empagliflozin, work by blocking glucose reabsorption in the kidneys, leading to intentional glycosuria. This loss of glucose in the urine causes an osmotic diuresis, resulting in more frequent urination. GLP-1 agonists like liraglutide and dulaglutide do not work via this mechanism. Insulin would be expected to decrease glycosuria by lowering blood glucose.
- In addition to its effects on insulin and glucagon secretion, liraglutide promotes weight loss. This is achieved partly through a central mechanism involving the activation of pro-opiomelanocortin (POMC) neurons, which increases satiety. In which region of the brain does this anorexigenic action primarily occur?
Answer: The arcuate nucleus of the hypothalamus
GLP-1 receptors are expressed in several areas of the brain. The key region for appetite regulation is the arcuate nucleus of the hypothalamus. GLP-1 agonists activate anorexigenic (appetite-suppressing) POMC neurons and inhibit orexigenic (appetite-stimulating) NPY/AgRP neurons in this area, leading to reduced food intake and weight loss. The area postrema (A) is the chemoreceptor trigger zone and is primarily associated with the nausea and vomiting side effects. The ventral tegmental area (C) and prefrontal cortex (D) are involved in reward and executive function, respectively, but are not the primary sites of POMC neuron activation for satiety by GLP-1.
- A 75-year-old patient with type 2 diabetes, hypertension, and heart failure is prescribed canagliflozin. The patient is also taking furosemide. Which physiological effect of canagliflozin presents both a therapeutic benefit for heart failure and a potential risk for this specific patient?
Answer: Natriuresis and osmotic diuresis, which improve heart failure symptoms but increase the risk of volume depletion.
SGLT2 inhibitors like canagliflozin cause natriuresis (excretion of sodium) and osmotic diuresis (excretion of water following glucose). This reduction in preload and fluid volume is a key mechanism for their benefit in heart failure. However, this same effect can lead to volume depletion, hypotension, and acute kidney injury, a risk that is significantly increased in an elderly patient who is also taking a loop diuretic like furosemide.
- Clinical trial data has raised concerns about an increased risk of bone fractures and decreased bone mineral density with a specific SGLT2 inhibitor, thought to be related to effects on mineral metabolism and volume status. Which agent has been most closely associated with this particular safety signal?
Answer: Canagliflozin
In the CANVAS program clinical trials, canagliflozin was associated with an increased risk of bone fractures and a decrease in bone mineral density at the hip and lower spine. The proposed mechanisms include effects on phosphate and parathyroid hormone levels, as well as potential volume depletion leading to falls. While this remains a topic of research, canagliflozin is the specific agent in the class most strongly linked to this adverse effect in major clinical trials.
- A 65-year-old male has type 2 diabetes, heart failure with a reduced ejection fraction (HFrEF) of 30%, stage 3b chronic kidney disease (eGFR 40 mL/min/1.73m²), and a history of recurrent pancreatitis. His current HbA1c is 8.5% on metformin. Which of the following is the most appropriate agent to add for glycemic control and management of comorbidities?
Answer: Dapagliflozin, as it has proven benefits in HFrEF and CKD and is not contraindicated by pancreatitis.
This is a multi-step reasoning question. The patient has compelling indications for an SGLT2 inhibitor (HFrEF and CKD). Dapagliflozin has strong evidence for improving outcomes in both of these conditions. The patient's history of recurrent pancreatitis is a significant caution or contraindication for GLP-1 agonists like semaglutide (A) and liraglutide (C). While canagliflozin (D) would also be a good choice for CKD/HF benefits, the history of pancreatitis does not require a dose adjustment for it. The critical step is recognizing that the pancreatitis history makes GLP-1 agonists inappropriate, leaving the SGLT2 inhibitors as the preferred class. Dapagliflozin is an excellent and safe choice in this context.
- A patient with an initial HbA1c of 9.5% and a fasting plasma glucose of 220 mg/dL is started on an SGLT2 inhibitor. The drug's glucosuric effect is known to plateau at higher plasma glucose concentrations. What is the primary reason for this plateau phenomenon?
Answer: The SGLT2 transporters become saturated with glucose, and SGLT1 transporters continue to reabsorb a fraction of the remaining glucose.
SGLT2 inhibitors block the majority of glucose reabsorption in the proximal tubule. However, as the filtered load of glucose increases, the transport capacity of the SGLT system can be saturated (Tmax). Furthermore, SGLT1 transporters located more distally in the proximal tubule are not inhibited and will reabsorb some of the glucose that bypasses the blocked SGLT2 transporters. This combination of transporter saturation and the continued action of SGLT1 leads to a plateau in urinary glucose excretion, even if plasma glucose continues to rise.
- A patient with a history of proliferative diabetic retinopathy is being considered for semaglutide therapy. The initiation and rapid titration of this agent requires careful monitoring for which specific ophthalmologic complication?
Answer: Worsening of pre-existing diabetic retinopathy
In the SUSTAIN-6 trial, a higher rate of diabetic retinopathy complications was observed with semaglutide compared to placebo. The leading hypothesis is that this is not a direct toxic effect of the drug, but rather a consequence of rapid and significant improvement in glycemic control in patients with pre-existing, advanced retinopathy. This phenomenon has been observed with intensive insulin therapy as well. Therefore, patients with a history of diabetic retinopathy should have regular ophthalmologic monitoring when starting a potent glucose-lowering agent like semaglutide.
- A patient taking an SGLT2 inhibitor for type 2 diabetes undergoes an elective surgical procedure and is advised to hold the medication for 3 days prior. What is the primary risk this temporary discontinuation is intended to mitigate?
Answer: The risk of perioperative euglycemic diabetic ketoacidosis.
The perioperative state (with fasting, surgical stress, and volume shifts) is a significant trigger for ketoacidosis. In patients taking SGLT2 inhibitors, this can manifest as euglycemic DKA. Standard guidelines recommend holding SGLT2 inhibitors for at least 3 days before major surgery to reduce this risk. While volume depletion (B) and AKI (D) are also concerns, the most specific and critical risk that this 'sick day rule' addresses is euglycemic DKA. Hypoglycemia (A) is not a major risk of SGLT2 inhibitors.
- Oral semaglutide is co-formulated with an excipient, sodium salcaprozil (SNAC). What is the primary function of SNAC in this unique formulation?
Answer: It locally increases gastric pH and facilitates the transcellular absorption of semaglutide across the gastric mucosa.
Semaglutide is a large peptide molecule that would normally be degraded by pepsin in the acidic environment of the stomach. SNAC is an absorption enhancer. It works by locally neutralizing the gastric acid (increasing pH), which reduces the degradation of semaglutide by pepsin. It also helps the large semaglutide molecule cross the gastric epithelial cell membrane (transcellular absorption). This allows for oral administration of a drug that would otherwise require injection. SNAC does not have DPP-4 inhibitor activity (A), does not work by further delaying gastric emptying (B), and does not form a prodrug (D).
